BioSpace News Archive

GenEros Biopharma Ltd. (“GenEros” or “the Company”) will unveil the preliminary data from the phase I clinical trial of GEC255, a unique KRAS G12C inhibitor, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Cognoa announced the expansion of its leadership team supporting the commercialization of Canvas Dx, the first and only FDA authorized diagnostic that gives diverse providers the ability to diagnose or rule out autism in children ages 1.5 to 6 years at risk of developmental delay.

Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Company”), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, today announced that its board of directors

Today Mymee Inc announced new peer-reviewed and payer-audited research that sheds light on the enormous challenges facing autoimmune patients with joint flares, >30 moderate to high frequency symptoms, and inadequate response to pharmacological treatments.

Cantex Pharmaceuticals, Inc. announced that it has obtained an exclusive worldwide license from Georgetown University for intellectual property related to the potential use of azeliragon to treat, prevent or alleviate cancer-treatment related cognitive decline.

Nykode Therapeutics ASA announced that it has expanded the clinical collaboration and supply agreement with Roche to cover evaluation of VB10.16, Nykode’s wholly owned off-the-shelf therapeutic cancer vaccine candidate, in combination with Roche’s cancer immunotherapy atezolizumab in patients with advanced cervical cancer who have progressed on pembrolizumab plus chemotherapy +/- bevacizumab as first line treatment.

Pharming Group N.V. announces that it has entered into a definitive agreement with Novartis Pharma A.G. to sell its Rare Pediatric Disease Priority Review Voucher to Novartis for a pre-agreed, one-time payment of approximately US$21.1 million shortly after closing.

Oxurion NV, a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced that the company will participate in three conferences in June:

invoX Pharma Limited announced that it has completed a second tranche of investment in pHion Therapeutics, a next-generation mRNA vaccine company.

Croma-Pharma announces that it will launch Pliaglis®, a topical local anaesthetic for superficial dermatological procedures, in its European core markets including Germany, the United Kingdom, and Ireland.